A Phase 1 interventional study of TA-8995 in Dyslipidemia, sponsored by Xention Ltd. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-03.
Sponsored by Xention Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.
Among the 14 studies testing TA-8995 in Dyslipidemias, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 1, and was the 5th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
NewAmsterdam Pharma · Sites in United States
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 30 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2015.
This study's enrollment of 6 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 116 across the 14 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 3 most frequent:
Xention Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.
Xention Ltd has 4 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
1 of the studies testing TA-8995 in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing TA-8995 in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TA-8995
AUC of TA-8995
Time frame: 35 days
Mass balance recovery of total radioactivity from excreta for radiolabelled TA-8995
Time frame: 35 days
Measure the amount of radiolabelled TA-8995 recovered from urine and faeces.
Time frame: 35 days
Measure the levels of major metabolites of TA-8995 in plasma, urine and faeces after oral administration of radiolabelled TA-8995
Time frame: 35 days
Elimination of half-life of radiolabelled TA-8995
Time frame: 35 days
Number of adverse events
Time frame: 35 days
The record gives a start of Jun 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
Xention Ltd